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I.

INTRODUCTION

For years, marijuana was a taboo subject in America. Recently,
however, medical marijuana has earned its place as the “scientifical,
mystical one,” finding legalization in many states even in the face of
federal prohibitions.1 Some laws authorizing even recreational use have
been enacted.2 It is undeniable that marijuana, recreational or medical, is
considered illegal under the federal Controlled Substances Act.3 With
states passing their own laws regarding usage, there is confusion
concerning the federal government’s enforcement priorities and its
position with regard to medical marijuana.4 For purposes of this
Comment, the terms medicinal and medical marijuana have the same
common meaning and are used interchangeably.
Part II of this Comment will address the state approaches to medical
marijuana by presenting a brief overview of legislation in several key
states to show how quickly support for usage has spread. Part III will
address the status of medical marijuana prior to 2015 and will discuss the
federal Controlled Substance Act (“CSA”) and other Congressional
measures regarding marijuana. It will also provide a brief overview of the
singular Supreme Court case on the issue, Gonzales v. Raich.5 In addition,
Part III will detail the role of the executive branch in marijuana
reclassification as well as discuss internal guidance from the Obama
Administration pertaining to prosecutorial discretion. Part IV will explain
the federal Farr-Rohrabacher Amendment and its impact on medical
marijuana. It will also discuss the Ninth Circuit’s analysis of the
Amendment in United States v. McIntosh.6 This section further highlights
1

Cypress Hill, Dr. Greenthumb, on Cypress Hill IV (Ruffhouse Records 1998).
See Ballotpedia, Alaska Marijuana Legalization, Ballot Measure 2 (2014),
https://ballotpedia.org/Alaska_Marijuana_Legalization,_Ballot_Measure_2_(2014);
Ballotpedia,
Maine
Marijuana
Legalization,
Question
1
(2016),
https://ballotpedia.org/Maine_Marijuana_Legalization,_Question_1_(2016); Ballotpedia,
Massachusetts
Marijuana
Legalization,
Question
4
(2016),
https://ballotpedia.org/Massachusetts_Marijuana_Legalization,_Question_4_(2016);
Ballotpedia,
Nevada
Marijuana
Legalization,
Question
1
(2016),
https://ballotpedia.org/Nevada_Marijuana_Legalization,_Question_2_(2016).
3 21 U.S.C. § 801 et. seq. (2012).
4 Steve Contorno, Barack Obama Says It’s Up to Congress to Change How Feds
Classify Marijuana, POLITIFACT (Feb. 4, 2014, 6:20 PM),
http://www.politifact.com/truth-o-meter/statements/2014/feb/04/barack-obama/barackobama-says-its-congress-change-how-feds-cla/.
5 545 U.S. 1 (2005).
6 833 F.3d 1163 (9th Cir. 2016).
2
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the conflict and contradiction of the federal prohibition on marijuana with
the actions of the executive and legislative branches in response to the
Farr-Rohrabacher Amendment.
Part V will detail a scientific argument for expanding access to
research for states in order to foster well-informed decisions over the fate
of medical marijuana. It will discuss several approaches the Trump
Administration may take and the likelihood of success with each. This
Comment will argue that it would be most beneficial to suspend
enforcement of the Controlled Substance Act, specifically as it applies to
medical marijuana. Suspension will be beneficial in order to allow the
states to experiment legally and to ultimately take the lead on the future of
medical marijuana, consistent with traditional norms of our federalist
system.
II. THE STATES AND MEDICAL MARIJUANA: A SPEEDY ACCEPTANCE
Unlike the federal government, many states have passed medical
marijuana laws that generally allow for the cultivation and use of
marijuana when recommended by a doctor to treat serious conditions.7
After a prohibition which originated in the early twentieth century,
California became the first state to allow the use of medical marijuana in
1996.8 The state’s Compassionate Use Act9 permits the use of medical
marijuana for serious health conditions, as determined by a state health
agency.10 It also allows for the treatment for other illnesses which may be
assuaged by marijuana.11 Two years later, Washington state followed
California and passed its own medical marijuana bill.12 Like California’s
law, Washington’s bill made the drug available for certain conditions that
are not relieved by standard treatment.13 Although Washington’s bill also
created an affirmative defense against state prosecution, it did not provide
protections against federal arrests.14 On the same day that Washington’s
bill was enacted, Oregon passed a medical marijuana law with similar
provisions and eligibility conditions as both California and Washington.15

7

Jay M. Zitter, Construction and Application of Medical Marijuana Laws and
Medical Necessity Defense to Marijuana Laws, 50 A.L.R.6th 353, § 2 (2017).
8 Troey E. Grandel, One Toke over the Line: The Proliferation of State Medical
Marijuana Laws, 9 U.N.H.L. REV. 135, 136 (2010).
9 Cal. Health & Safety Code § 11362.5 (Lexis 2017).
10 See Grandel, supra note 8 at 141–142.
11 Id.
12 Id. at 142
13 Id.
14 Id.
15 See Grandel, supra note 8 at 142–43.
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Since then, a number of states have passed legislation allowing for
“comprehensive public medical marijuana and cannabis programs.”16 In
these states, patients are typically required to provide a doctor’s written
authorization as well as obtain a prescription, subject to select conditions
and diseases.17 Some states, such as Colorado, also allow for the limited
use of Cannabidiol (“CBD”)18 products for medical reasons or as a legal
defense.19 Alaska, Colorado, Oregon, Washington, and the District of
Columbia have all authorized marijuana use in small amounts for
recreational purposes.20 Other states, such as New Hampshire and
Vermont have proposed legislation to legalize marijuana by removing
criminal penalties for its use and possession.21 In the 2016 election cycle,
four states voted and approved medical marijuana measures to expand or
establish its availability for medical purposes.22 Despite all of these state
reforms and initiatives, marijuana is still illegal under federal law.

16 State Medical Marijuana Laws, MEDICINAL CANNABIS CONFERENCE (Mar. 1, 2017),
http://www.medicinalcannabisconference.com/?p=896. The states include Alabama,
Alaska, Arizona, Arkansas, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii,
Illinois, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan,
Minnesota, Mississippi, Missouri, Montana, Nevada, North Dakota, New Hampshire, New
Jersey, New Mexico, New York, North Carolina, Oklahoma, Rhode Island, South Carolina,
Tennessee, Texas, Utah, Vermont, Virginia, Wisconsin, and Wyoming, the District of
Columbia, Guam, and Puerto Rico. See Dean M. Nickles, Federalism and State Marijuana
Legislation, 91 NOTRE DAME L. REV. 1253 (2016); See also The National Conference of
State Legislatures, Medical Marijuana Laws, http://www.ncsl.org/research/health/statemedical-marijuana-laws.aspx.
17 Beth P. Zoller, Hazy Future: Reconciling Federal and State Laws on Marijuana
Use, XpertHR Legal Insight 9666 (Lexis 2017).
18 Unlike delta-9 tetrahydrocannabinol (“THC”), which causes the high, CBD is not
intoxicating and does not cause a high; it is cited as one of the reasons why the restrictions
on
marijuana
should
be
relaxed.
See
Nora
Volkow,
Researching Marijuana for Therapeutic Purposes: The Potential Promise of Cannabidiol (CBD), THE
HUFFINGTON
POST
(Jul.
23,
2016),
http://www.huffingtonpost.com/noravolkow/cannabidiol_b_7834066.html.
19 See Volkow, supra note 18.
20 See Ballotpedia, supra note 2.
21 See Zoller, supra note 17.
22 Katy Steinmetz and David Johnson, Election 2016: States Where Marijuana Is on
the Ballot, TIME (Nov. 4, 2016), http://time.com/4557417/election-2016-marijuana-potlegal-ballot/; See also Ballotpedia, North Dakota Medical Marijuana Legalization,
Initiated
Statutory
Measure
5
(2016),
https://ballotpedia.org/North_Dakota_Medical_Marijuana_Legalization,_Initiated_Statut
ory_Measure_5_(2016); Ballotpedia, Florida Medical Marijuana Legalization, Amendment
2
(2016),
https://ballotpedia.org/Florida_Medical_Marijuana_Legalization,_Amendment_2_(2016);
Ballotpedia, Arkansas Medical Marijuana Amendment, Issue 6 (2016),
https://ballotpedia.org/Arkansas_Medical_Marijuana_Amendment,_Issue_6_(2016);
Ballotpedia,
Montana
Medical
Marijuana
Initiative,
I-182
(2016),
https://ballotpedia.org/Montana_Medical_Marijuana_Initiative,_I-182_(2016).
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III. THE STATUS OF MEDICAL MARIJUANA UNDER FEDERAL LAW
THROUGH 2015
The federal government prohibits the use of marijuana completely,
even if used for medicinal purposes.23 However, a closer examination
shows that there are discrepancies amongst the three branches regarding
how strictly this prohibition is viewed. Subsection A will address the
Congressional approach to medical marijuana. It will detail relevant
sections of the CSA as well as illustrate more recent legislative efforts,
suggesting that at least some members of the legislative branch are open
to the acceptance of medical marijuana. Subsection B will review the
Supreme Court’s stance on medical marijuana as cemented in Gonzales v.
Raich.24 Finally, Subsection C will discuss the executive branch’s role
under the CSA, including the various agencies involved in the
rescheduling considerations to remove Marijuana from the list of Schedule
I drugs as well as the enforcement of federal law, including internal
guidance issued on medical marijuana. This section will also address a
failed attempt by the executive and the legislative branches to reclassify
medical marijuana.
A. Congress
Marijuana is illegal under federal law. More specifically, it is highly
regulated under the CSA and is classified as a Schedule I drug, the most
restrictive classification.25 The CSA classifies drugs as Schedule I if they
(1) have a “high potential for abuse,” (2) have “no currently accepted
medical use in treatment in the United States,” and if (3) “[t]here is a lack
of accepted safety for use of the drug . . . under medical supervision.”26
Schedule I drugs may be lawfully obtained and used only by doctors who
have submitted a detailed research protocol for approval to the Food and
Drug Administration (“FDA”), and who agree to abide by strict rules
pertaining to recordkeeping and storage rules.27 Further, the Attorney
General, under the authority of the Drug Enforcement Administration
(“DEA”) may reschedule a drug if he or she finds that the drug no longer
meets the criteria under the schedule for which it has been assigned.28 This
decision is based upon “[s]cientific evidence of [the drug’s]

23
24
25
26
27
28

21 U.S.C. § 812(c)(10) (2012).
545 U.S. 1 (2005).
See 21 U.S.C. § 812, Supra note at 23.
Id. § 812(b)(1).
Id.
Id.

130

SETON HALL CIRCUIT REVIEW

[Vol. 14:125

pharmacological effect, if known,” and “[t]he state of current scientific
knowledge regarding the drug or other substance.”29
Drugs classified under Schedule II are those that (1) have a high
potential for abuse; have a currently accepted medical use as treatment or
are currently accepted with severe restrictions; and (3) if abused, may lead
to severe psychological or physical dependence.30 For a drug to be
classified as Schedule III, IV, or V, those which are deemed acceptable for
medical treatment, the Attorney General must verify the following: (1) the
drug’s chemistry is known and reproducible; (2) there are adequate safety
studies; (3) there are adequate and well-controlled studies proving
efficacy; (4) the drug is accepted by qualified experts; and (5) there is
scientific evidence widely available.31
For over forty-five years, the federal government has exercised
almost exclusive control over research-grade marijuana, and has refused
to allow for privately-funded and FDA-approved operations on researchgrade marijuana.32 While marijuana has throughout history been
extensively used and researched,33 no Attorney General has taken the
initiative to modify the drug’s current classification as Schedule I.34
In March 2015, over a year before the DEA issued its official refusal
to reclassify medical marijuana,35 Republican House Representative Scott
Perry (PA) introduced the Charlotte’s Web Medical Help Act.36 The Act
called for the exclusion of “therapeutic hemp and cannabidiol from the
definition of marihuana [sic], and for other purposes.”37 The bill’s
namesake was a seven-year-old girl, Charlotte Figi, who suffered from
Dravet Syndrome, a rare form of epilepsy.38 After moving to Colorado
29

Ams. for Safe Access v. DEA, 706 F.3d 438, 441 (D.C. Cir. 2013).
§ 812(b)(2) (2012).
31 Ams. for Safe Access, 706 F.3d. at 441.
32 Ruth C. Stern and J. Herbie DiFonzo, The End of the Red Queen’s Race: Medical
Marijuana in the New Century, 27 QUINNIPIAC L. REV. 673, 707 (2009).
33 See Grandel, supra note 8 at 136–39.
34 See generally Department of Justice, Drug Enforcement Administration, 21 C.F.R.
Chapter 11, Docket No. DEA426, Denial of Petition to Initiate Proceedings to Reschedule
Marijuana
(Aug.
12,
2016),
available
at
https://www.federalregister.gov/documents/2016/08/12/2016-17954/denial-of-petition-toinitiate-proceedings-to-reschedule-marijuana. [Hereinafter 2016 DEA Denial].
35 Id.
36 Charlotte’s Web Medical Hemp Act of 2014, H.R. 5226, 113th Cong. (2014).
37 Id.
38 Hannah Osborne, Charlotte Figi: The Girl Who is Changing Medical Marijuana
Laws Across America, INTERNATIONAL BUSINESS TIMES (Jun. 20, 2014),
http://www.ibtimes.co.uk/charlotte-figi-girl-who-changing-medical-marijuana-lawsacross-america-1453547; Matt Ferner, House Bill Would Legalize ‘Charlotte’s Web’
Medical
Marijuana,
THE
HUFFINGTON
POST
(Jul.
29,
2014),
http://www.huffingtonpost.com/2014/07/28/medical-marijuanalegalization_n_5627810.html.
30
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with her family and obtaining the help of a non-profit organization,
Charlotte’s seizures were successfully treated “with a strain of high-CBD,
low-THC medical cannabis called ‘Charlotte’s Web.’ Traditional
pharmaceuticals failed to help Charlotte.”39 In general, there is genuine
debate over the actual medicinal advantages for marijuana in general.40
That being said, it is counterintuitive to hinder additional research on the
success of THC-based extracts in treating serious conditions, such as
epilepsy (particularly in children); this research could yield real medical
benefits, which may save the lives of those for whom traditional treatment
options do not work. As of the writing of this Comment, Representative
Perry’s act has not advanced beyond referral to the Subcommittee on
Crime, Terrorism, Homeland Security, and Investigations.41
B. The Supreme Court
In 2005, the Supreme Court decided its only medical marijuana case
to date.42 The respondents in Gonzales v. Raich were residents of
California who sought relief from various medical conditions through
procurement of medical marijuana, an action that was permissible under
the state’s Compassionate Care Act.43 After unsuccessful results from
conventional drugs, board-certified family practitioners treated the
respondents with marijuana, as it was the only drug that provided relief.44
In August 2002, county deputy sheriffs and DEA agents came to the house
of one of the respondents, conducted a thorough investigation and
concluded that her use of marijuana was lawful under California law. Still,
the agents seized and destroyed all six cannabis plants present.45 At trial,
the respondents sought injunctive relief from enforcement under the CSA
given the conflict between state law and their legitimate and serious
medical conditions.46 They argued that enforcing the CSA was a violation
of various constitutional principles, as well as and the doctrine of medical
necessity.47

39

Id.
See 2016 DEA Denial, supra note 34; see also Craig Press, Kelly Knupp, and Kevin
Chapman, Parental Reporting of Response to Oral Cannabis Extracts as Adjunctive
treatment for Medically Refractory Epilepsy, in American Epilepsy Society Annual
Meeting
Abstracts
(Abst.
1.326,
2014),
available
at
https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/1868031.
41 Charlotte’s Web Medical Access Act of 2015, H.R. 1635, 114th Cong. (2015).
42 Gonzales v. Raich, 545 U.S. 1 (2005).
43 Id. at 6–7.
44 Id. at 7.
45 Id.
46 Id.
47 Id. at 8.
40
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The Supreme Court was not persuaded. In Justice Stevens’ majority
opinion, the Court applied the rational basis test, and found that “Congress
was acting well within its authority to ‘make all [laws] which shall be
necessary and proper’” by enacting the CSA; this justified the federal
government’s seizure of the respondent’s marijuana.48 Echoing Wickard
v. Filburn, the Court strongly emphasized that Congress possesses the
authority to regulate interstate commerce, even in instances where noncommercial, intrastate activities could undercut regulation of the interstate
market.49 In essence, Congress may still regulate a “local” activity
because that activity may have a substantial economic effect on interstate
commerce.50 The Gonzales Court determined that the CSA applied to the
respondents by virtue of the Supremacy Clause, and that “Congress had a
rational basis for concluding that leaving home-consumed marijuana
outside federal control would similarly affect price and market
conditions.”51
Gonzales, however, was not a unanimous decision. Writing for the
dissent, Justice O’Connor was critical of the reliance on Wickard and
rallied for federalism.52 In reassessing the scope of the Commerce Clause
in tandem with the CSA to account for medical use of marijuana, Justice
O’Connor reasoned that respondents’ private actions did not have a
substantial impact on commerce because their private action failed the
Wickard steam of commerce test; their private actions could not, therefore,
impact the national market.53 She also noted that the majority’s
application of the Necessary and Proper Clause did still require the federal
government to honor “basic constitutional principles.”54 Further, Justice
O’Connor argued that Wickard “did not hold or imply that personal-sized
or small-scale productions are always economic and are automatically
within Congress’s reach.”55
Justice O’Connor also proposed that medical marijuana be regulated
separately from general recreational use, suggesting that the majority’s
reading of the CSA was far too broad and creates unnecessary federalism
issues.56 In her view, the action by the federal government was
48

Gonzales, 545 U.S. at 22 (citing U.S. CONST. art. 1, 8, cl. 18). See also Casey L.
Carhart, Will the Ever-Swinging Pendulum of Commerce Clause Interpretation Ever Stop?
A Casenote on Gonzales v. Raich, 27 WHITTIER L. REV. 833, 835 (2006).
49 Gonzales, 545 U.S. at 17–18 (citing Wickard v. Filburn, 317 U.S. 111 (1942)).
50 Wickard, 317 U.S. at 124–25.
51 Gonzales, 545 U.S. at 19, 29.
52 Id. at 42 (O’Connor, J., dissenting).
53 See Carhart, supra note 48, at 848.
54 Id. at 847.
55 Gonzales, 545 U.S. at 51 (O’Connor, J., dissenting).
56 Id. at 48; see also Carhart, supra note 48 at 847.
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unconstitutional because California voters had decided—by ballot and by
legislation—to legalize the drug, and thus any interference on the part of
the federal government would deny a state the ability to give effect to its
own laws.57 For Justice O’Connor, it was within the states’ core powers
to define their own criminal law and to protect their citizens.58 The federal
government’s power to, at will, interfere with a state’s traditional police
power is problematic for any state wishing to decriminalize or legalize
marijuana. Justice O’Connor argued that the Court’s decision in Gonzales
is “irreconcilable” with its own prior precedent in cases not dealing with
marijuana.59 Post-Gonzales, it appears, states have taken Justice
O’Connor’s dissent seriously. The majority’s ruling has not stopped states
like Rhode Island, Montana, Michigan, New Jersey, or the District of
Columbia from enacting their own medical marijuana laws in the
aftermath of this decision.60
C. The Executive Branch
The executive branch enforces the regulation of marijuana through
various agencies. Under 28 U.S.C. § 811, the Attorney General, of the
Department of Justice (“DOJ” or “the Department”) may add or remove
drugs from the schedules as long as there is, for example, evidence of
potential for abuse.61 Congress, however, may decide to reschedule
marijuana or remove it entirely from the Controlled Substance Act.62 The
DEA, the FDA, the Department of Health and Human Services (“HHS”),
and the National Institute on Drug Abuse (“NIDA”) are all important
agencies in medical marijuana rescheduling considerations. The DEA
gathers necessary data on a drug and subsequently requests a scientific and
medical evaluation and scheduling recommendation from Secretary of
HHS.63 Administrative responsibilities for evaluating a substance for
control under the CSA are performed by the FDA, with NIDA’s
concurrence.64
57 Wilson Ray Huhn, The Constitutional Jurisprudence of Sandra Day O’Connor: A
Refusal to “Foreclose the Unanticipated”, 39 AKRON L. REV. 373, 413.
58 Gonzales, 545 U.S. at 43 (O’Connor, J., dissenting).
59 Id. For additional discussions regarding the use and limitations of Congress’s ability
to act pursuant to the Commerce Clause, See United States v. Lopez, 514 U.S. 549, 551
(1995) (finding that possession itself is not commercial activity); See also United States v.
Morrison, 529 U.S. 598, 611 n.4 (2000) (intrastate activities that may be regulated by
Congress must be of an “apparent commercial character”).
60 Grandel, supra note 8 at 139; see also Cal. Health & Safety Code § 11362.5 (1996).
61 21 U.S.C. 811 (a)(1)(A) (2012), see also 2016 DEA Denial, supra note 34.
62 See Contorno, supra note 4.
63 21 U.S.C. § 811 (b) (2017).
64 Memorandum of Understanding with the National Institute on Drug Abuse 50 FR
9518-02 (March 8, 1985).
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The DOJ has seen a fluctuation in domestic marijuana seizures since
1984.65 In 2014, the total number of seizures was at its lowest since 1986
with 74,225.66 The decline late in the Obama Administration potentially
corresponds with the three internal guidance memoranda utilized by the
Department. Beginning in 2009, the DOJ issued memos to its prosecutors
regarding their responsibilities in terms of states with medical marijuana
laws. In the initial memorandum, then-Deputy Attorney General David
Ogden emphasized that the priority of the Department was to prosecute
criminal enterprises that create illegal markets to sell marijuana as opposed
to prosecuting individuals with serious illnesses who use marijuana
consistent with state law.67 The DOJ was to continue its due diligence in
investigations, but it would not be quick to prosecute marijuana usage
claims in states that allowed medical use.68 Ogden cautioned, however,
that compliance in such states may be done to mask illegal operations, and
that prosecutions should be made on a case-by-case basis in order for the
federal government to remain consistent with guidelines on resource
allocations and priorities.69
In 2013 and 2014, the Department clarified its earlier guidance and
noted that while state laws authorizing marijuana production, distribution,
and possession contrast with federal-state narcotics enforcement, the
federal government is less threatened by states that have implemented
strong, effective regulatory and enforcement schemes to oversee various
forms of marijuana usage.70 The subsequent memos once again expressed
prosecutorial discretion in instances of chronically ill individuals abiding
by state law as opposed to commercial enterprises; they noted that if states
65

Drug
Enforcement
Administration,
Statistics
&
Facts,
https://www.dea.gov/resource-center/statistics.shtml.
66 See id.; see also Drug Enforcement Administration, 2015 Final Domestic Cannabis
Eradication/Suppression
Program
Statistical
Report,
available
at
https://www.dea.gov/ops/cannabis_2015.pdf;
2014
Domestic
Cannabis
Eradication/Suppression
Statistical
Report,
available
at
https://www.dea.gov/ops/cannabis_2014.pdf.
67 David Ogden, Memorandum for Selected United States Attorneys re: Investigations
and Prosecutions in States Authorizing the Medical Use of Marijuana, Oct. 19, 2009,
available
at
https://www.justice.gov/opa/blog/memorandum-selected-united-stateattorneys-investigations-and-prosecutions-states [hereinafter Ogden Memo]; James M.
Cole, Memorandum for All United States Attorneys re: Guidance Regarding Marijuana
Enforcement,
Aug.
29,
2013,
available
at
https://www.justice.gov/iso/opa/resources/3052013829132756857467.pdf
[hereinafter
2013 Cole Memo]; James M. Cole, Memorandum for All United States Attorneys re:
Guidance Regarding Marijuana Related Financial Crimes, Feb. 14, 2014, available at
http://www.dfi.wa.gov/documents/banks/dept-of-justice-memo.pdf [hereinafter 2014 Cole
Memo]
68 See Ogden Memo, supra note 67.
69 Id.
70 See 2014 Cole Memo, supra note 67.
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lack “robust” enforcement efforts, the federal government may challenge
the regulatory structure as well as pursue legal action.71 With this
guidance, the federal government may take action against states, despite
the presence of strong state regulatory structures, if certain conduct or
people threaten federal priorities.72 The discretion allotted in the guidance
and in state laws does not constitute valid defenses to any action taken by
the federal government in terms of enforcement.73 The federal
government may always act to enforce, but the guidance gives states and
marijuana users insight as to when the federal government is likely to do
so. The DOJ charged its attorneys with monitoring conditions in the states
in order to assess when to use its limited budget for prosecutions, but it
has not provided specificity as to how it will monitor users within states
with medical marijuana laws.74
Simply because there is prosecutorial discretion regarding
enforcement does not mean the DEA under President Obama was eager to
reclassify marijuana from Schedule I. In November 2011, then-Governors
Lincoln D. Chafee (RI) and Christine O. Gregoire (WA) petitioned the
DEA to reclassify marijuana away from Schedule I and repeal the relevant
rules and regulations that kept it as such.75 The petition stated that
“cannabis has an accepted medical use in the United States, is safe for use
under medical supervision, and has a relatively low abuse potential
compared to other Schedule II drugs.”76 The DEA requested scientific and
medical evaluation and schedule recommendations from HHS, which
ultimately found that marijuana possesses a high potential for abuse, has
no accepted medical use in the United States, and lacks the appropriate
level of safety for use under medical supervision.77 The DEA formally
rejected the request to reclassify marijuana in July 2016.78 In its report,
the agency noted that the FDA approval of a New Drug Application is not
the only means through which a drug can be determined to have an
71

Id.
See 2014 Cole Memo, supra note 67.
73 Id.
74 See generally U.S. Gov’t Accountability Office, GAO-16-1, Report to
Congressional Requesters: State Marijuana Legalization, DOJ Should Document Its
Approach
to
Monitoring
the
Effects
of
Legalization
(2015),
http://www.gao.gov/assets/680/674464.pdf.
75 U.S. Department of Justice, Schedule of Controlled Substances: Maintaining Marijuana
in
Schedule
I
of
the
Controlled
Substance
Act
(2016),
1,
https://www.deadiversion.usdoj.gov/schedules/marijuana/Maintaining%20Marijuana%20
in%20Schedule%20I%20of%20the%20Controlled%20Substances%20Act.pdf.
76 Id.
77 Id. at 2. For discussion regarding the specific reasoning the DEA gave for these
categories, see id. at 54–75.
78 See generally id.
72
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accepted medical use in treatment in the United States.79 Citing to Alliance
for Cannabis Therapeutics v. DEA,80 the DEA outlined a five-part test to
determine if a drug has a “currently accepted medical use”81 in the United
States: “(1) the drug’s chemistry must be known and reproducible . . . ; (2)
there must be adequate safety studies . . . ; (3) there must be adequate and
well-controlled studies proving efficacy . . . ; (4) the drug must be
accepted by qualified experts . . . ; and (5) the scientific evidence must be
widely available[.]”82
In examining these prongs, HHS concluded that marijuana does not
meet any of the requirements.83 More specifically, the HHS determined
that marijuana’s chemistry is such that (1) a standardized dose cannot be
created due to the irreproducibility of the drug; that the variation of the
drug’s chemistry complicates safety evaluations; (2) that there are no
adequate or well-controlled studies to document marijuana’s efficacy; (3)
that there is currently no evidence of a consensus amongst qualified
experts that marijuana is an effective and appropriate treatment measure;
(4 and 5) and that the current data on the drug is insufficient to allow for
scientific scrutiny, emphasizing that the chemistry of a specific cannabis
strain suggesting standardization and reproducibility does not exist.84
Despite the efforts of Governors Chafee and Gregorie to show that there
was evidence of acceptance in the medical community and that the
chemistry is known and reproducible, the DEA found that “informative,
conclusions on long-term use of marijuana cannot be applied to the general
population.”85
The federal government’s refusal to reconsider its stance is
interesting (or noteworthy), in light of the fact that marijuana is the only
Schedule 1 drug that non-DEA-licensed private laboratories and
researchers are not allow to produce in a scientific study environment.86
In 2007, a DEA Administrative Law Judge recommended a University of
Massachusetts professor be granted permission by the DEA to grow
marijuana for medical purposes after her petition had been pending for six
years.87 The Administrative Law Judge found “the existing supply of
licensed cannabis inadequate, [deeming the] application to cultivate
marijuana for research purposes to be ‘in the public interest’ and
79
80
81
82
83
84
85
86
87

Id. at 32.
15 F.3d 1131 (D.C. Cir. 1994).
See 2016 DEA Denial, supra note 34 at 53700.
Id. at 53739.
Id. at 53700.
Id. at 53700–01.
Id. at 53760; see also infra Part V.
See Stern and DiFonzo, supra note 32 at 707.
Id.
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recommended it be granted.”88 The determination, however, was subject
to review by the DEA Administrator and, as with the Administrative Law
Judge’s earlier decision on rescheduling, was rejected.89 However, not all
those who seek authorization to research are denied; they may just have to
wait a decade or so.90
In 2008, the American College of Physicians prepared a position
paper strongly supporting “increased research and evaluation on
marijuana’s therapeutic benefits.”91 It boldly noted that the overly strict
federal government oversight created a “clear discord . . . between the
scientific community and federal, legal, and regulatory agencies over the
medical value of marijuana, which impedes the expansion of research.”92
Similarly, in 2009, the American Medical Association put forth a report
cited by Governors Chafee and Gregorie’s 2011 request.93 The report
accepted marijuana’s safety and efficacy, but cautioned that: (1) it was not
endorsing state-based medical marijuana programs; (2) was not
advocating for the legalization of marijuana, and; (3) was not suggesting
that scientific evidence on the therapeutic use of cannabis meets the same
and current standards for a prescription drug product.94
IV. THE FARR-ROHRABACHER AMENDMENT: THE FEDERAL
GOVERNMENT VS. THE FEDERAL GOVERNMENT IN 2015 AND BEYOND
Through 2015, the states that passed their own legislation legalizing
medical marijuana did so despite federal prohibitions. Congress, which
has outlawed marijuana under the CSA, has also proposed laws that would
allow for the use of marijuana-derivatives to treat medical conditions.95
Likewise, memoranda exists from the DOJ promoting prosecutorial
discretion in states that have legalized medical marijuana, despite the
Department’s role in enforcing the CSA.96 Inevitably, the consequences
88

Id.
Id.
90 See also Janet Burns, Trump Extends Cannabis Protections ‘Til December as Plans
for
Study,
States
Remain
Hazy,
Forbes
(Date
of
Access), https://www.forbes.com/sites/janetwburns/2017/09/25/trump-budget-extendscannabis-protections-til-december-as-plans-for-study-states-remain-hazy/#c77e5c947ffe
(“Last year, the DEA began accepting applications to grow more cannabis for research,
and it’s reportedly received 25 such proposals as of this month. In order to proceed,
however, researchers would need the Justice Department’s approval, and have so far come
up entirely short.”) (last visited Jan. 1, 2018).
91 Stern DiFonzo, supra note 32 at 708.
92 Id. (internal citation omitted).
93 See 2016 DEA Denial, supra note 34 at 53756.
94 Id. (internal citations omitted).
95 See supra Part III, Section A.
96 See supra Part III, Section C.
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of conflicting enforcement policies have led to a shift in oversight. In
2015, Congress passed a spending bill that included the Farr-Rohrabacher
Amendment, which gave states with medical marijuana laws a reprieve
from inconsistent federal enforcement.97 Subsection A will detail the FarrRohrabacher Amendment itself.
Subsection B will explore the
implications of the Amendment, including McIntosh, a case in which the
Ninth Circuit upheld the constitutionality of the Amendment.98 Section C
will focus on the aftermath of McIntosh as faced by Congress and by the
executive branch.
A. The Farr-Rohrabacher Amendment
In December 2015, Congress passed the Consolidated
Appropriations Act 2016, which President Obama signed on the same
day.99 Section 538 is referred to as the Farr-Rohrabacher Amendment
(“the Amendment” or “§ 538”).100 It was co-sponsored by Democratic
Representative Sam Farr (CA) and Republican Representative Dana
Rohrabacher (CA). The Amendment took many forms, while continually
offered for debate in the House of Representatives since 2003.101 While
the Amendment first formally appeared in the 2015 omnibus bill, it was
the 2016 Amendment, containing the same language, which was at issue
in McIntosh, discussed in Subsection B below.102 The Amendment
provides as follows:
None of the funds made available in this Act to the Department of
Justice may be used, with respect to any of the States of Alabama, Alaska,
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia,
Hawaii, Illinois, Iowa, Kentucky, Louisiana, Maine, Maryland,
Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana,
Nevada, New Hampshire, New Jersey, New Mexico, New York, North
Carolina, Oklahoma, Oregon, Rhode Island, South Carolina, Tennessee,
Texas, Utah, Vermont, Virginia, Washington, Wisconsin, and Wyoming,
97

See infra, Part IV, Section A.
833 F.3d 1163.
99 Consolidated Appropriations Act 2016, Pub. L. No. 114-113, 114 Cong. (2015).
100 In the previous spending bill, Consolidated and Further Continuing Appropriations
Act 2015, Pub. L. No. 113-235, 113 Cong. (2014), the Amendment is located at Section
538, available at: https://www.congress.gov/113/plaws/publ235/PLAW-113publ235.pdf.
101 Douglas H. Fischer, Clearing the Smoke Around the Farr-Rohrabacher Amendment,
LAW360.COM
(Mar.
10,
2015,
12:35
PM),
https://www.law360.com/articles/628782/clearing-the-smoke-around-the-farrrohrabacher-Amendment.
102 See United States v. Firestack-Harvey, 2014 U.S. Dist. LEXIS 60959, 2014 WL
1744255 (relying on a previous iteration of the appropriation bill). Reader should note that
the Amendment language is consistent in the appropriations bills. See also Fischer, supra
note 101.
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or with respect to the District of Columbia, Guam, or Puerto Rico, to
prevent any of them from implementing their own laws that authorize the
use, distribution, possession, or cultivation of medical marijuana.103
By pulling on the purse strings, Congress is protecting states with
valid laws only from prosecution. It does not prohibit the federal
government from surveilling states irrespective of marijuana laws or from
prosecuting individuals in those states without medical marijuana
legalization laws.104 The Amendment was included in past appropriation
bills105 and was allotted for in the 2017 Appropriations Acts.106 At the
time of the 2016 Appropriations Bill, Representative Farr remarked that
the Amendment served not only to protect the states with medical
marijuana laws from federal intrusion, but also residents who lawfully
comply with those state laws from apprehension by the federal
government.107 Representative Farr cited a Pew Research Center survey
which found that 61% of Republicans and 76% of Independents favored
legalization of medical marijuana and argued that shifting social opinions
were influential in including this Amendment.108
Much of the
Congressional record reflects similar arguments made in the 2016 DEA
report,109 namely, that there is no medical evidence for such claims of
efficacy and that the drug is highly addictive.110 Ultimately, the arguments
103

See supra note 99 at § 542.
See infra Part IV, Section C; see also Daniel J. Hurteau, et al., Confusion Persists
over Medical Marijuana Enforcement, LAW360.COM (Jan. 15, 2015, 2:12 PM),
https://www.law360.com/articles/613191/confusion-persists-over-medical-marijuanaenforcement.
105 See supra note 100.
106 See 114 P. L. 114-223 (Lexis 2017) (“The following sums are hereby appropriated,
out of any money in the Treasury not otherwise appropriated, and out of applicable
corporate or other revenues, receipts, and funds, for the several departments, agencies,
corporations, and other organizational units of Government for fiscal year 2017, and for
other purposes . . . [including]: The Commerce, Justice, Science, and Related Agencies
Appropriations Act, 2016 (division B of Public Law 114–113)”). To avoid a government
shutdown following the appropriation’s September 20, 2016 expiration date, Congress
extended the amendment under the Continuing Appropriations and Military Construction,
Veterans Affairs, and Related Agencies Appropriation Act, 2017, and Zika Response and
Preparedness Act. See also 114 P. L. 114-254 (further extending appropriations through
April 28, 2017).
107 160 Cong. Rec. H4982-85 (daily ed. May 29, 2014); see also Brief of Members of
Congress Rohrabacher (R-CA) and Farr (D-CA) as Amici in Support of Charles C. Lynch’s
Motion for Rehearing En Banc, United States v. Lynch, Nos. (9th Cir. 2015) (Nos. 1050219, 10-50264).
108 160 Cong. Rec. H4982-85, H4983 (daily ed. May 29, 2014); see also Public Support
for Legalizing Medical Marijuana, Pew Research Center (Apr. 1, 2010),
http://www.people-press.org/2010/04/01/public-support-for-legalizing-medicalmarijuana/.
109 See supra Part III. See generally 2016 DEA Denial, supra note 34.
110 160 Cong. Rec. H4982-85, H4985 (daily ed. May 29, 2014).
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were not persuasive and the House of Representatives passed the
appropriations bill with the Amendment in it on April 30, 2015, by a vote
of 255-163.111 Of those 255 votes of “yea,” 236 were Republicans and 19
were Democrats.112 On November 10, 2015, the Senate passed the bill with
changes, which required the House’s approval.113 The collective bill was
approved on December 18, 2015 with a vote in the Senate of 65-33, with
27 Republicans and 37 Democrats agreeing with the passage.114
Numerous questions arise from such vague language concerning
enforcement, executive power, and the fact that federal government’s
attention is still not fully diverted from marijuana, even for medical
purposes.115 As will be shown in Subsection B, courts engage in narrow
interpretation when there is a dispute over congressional intent, since
Amendments do not follow the same legislative process as regular laws
and the stakes are very high.116 Appropriation Amendments are a clever,
though controversial, way for Congress to exert dominance over executive
power.117
B. United States v. McIntosh: The Ninth Circuit’s Dance with Mary
Jane
In August 2016, the Ninth Circuit upheld the constitutionality of the
Farr-Rohrabacher Amendment.118
In McIntosh, ten cases were
consolidated on interlocutory appeals and petitions for writs of mandamus
from appellants who were indicted for various infractions under the
CSA.119 In McIntosh, five co-defendants allegedly ran four marijuana
stores in the Los Angeles and San Francisco areas and were indicted for
conspiracy to: manufacture; possess with intent to distribute; and
distribute more than 1,000 marijuana plants in violation of the CSA.120 In
United States v. Lovan, the DEA and the Fresno County Sheriff’s Office
executed a federal search warrant on land located in Sanger, California,
where more than 30,000 marijuana plants were found on the property,
leading to the indictment of four co-defendants in violation of the CSA.121

111 Actions Overview H.R.2029 – 114th Congress (2015-2016), available at
https://www.congress.gov/bill/114th-congress/house-bill/2029/actions.
112 Id.
113 Consolidated Appropriations Act, H.R. 2029, 114th Cong. (2016).
114 Id.
115 See Hurteau et al., supra note 104.
116 Id.
117 See Fischer, supra note 101.
118 McIntosh, 833 F.3d at 1168.
119 Id. at 1169–70.
120 Id. at 1169.
121 Id.
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In the final consolidated case, United States v. Kynaston, five codefendants faced charges relating to Washington State’s Controlled
Substance Act, which lead to an ultimate indictment under the CSA, as
well as illegal firearm possession.122 In McIntosh and Kynaston, the lower
courts found that the defendants did not meet the burden necessary to
demonstrate compliance with state medical marijuana laws, and denied the
motions to dismiss or to enjoin on the basis of the Amendment from the
bench.123 In Lovan, the court found that a jury trial was necessary to
determine if defendants complied with state law, and that the motion to
dismiss would only be revisited post-trial.124
On appeal, the Ninth Circuit noted that these cases were unusual, as
federal criminal prosecutions do not typically provide for injunctive relief
and interlocutory appeals for ongoing litigation.125 Congress’s enactment
of the Amendment led the court to note that it is “the exclusive province
of the Congress not only to formulate legislative policies and mandate
programs and projects, but also to establish [its] relative priority for the
Nation.”126 Moreover, the court stated that, once Congress delegates its
powers or otherwise prioritizes a certain area, it is up to courts to enforce
such policies when enforcement is sought.127 As such, the court found that
it could not “ignore the judgment of Congress”, one that was “deliberately
expressed in legislation” and is authorized to exercise jurisdiction if a
district court denies a request for injunctive relief.128 The court limited the
scope of its analysis in a footnote, stating that it did not need to decide how
the district courts should resolve claims that the DOJ is in violation of the
Amendment. 129
The court based its decision on several factors, including its
understanding of the Amendment text, and then engaged in statutory
interpretation.130 In addressing the Amendment, the court stated, “[n]o
money shall be drawn from the treasury, but in consequence of
appropriations made by law . . . .”131 Appellants argued, and the court
agreed, that if the DOJ were spending money in violation of § 542 of the
Amendment, it would be in violation of the Constitution, furthering their
122

Id.
Id.
124 McIntosh, 833 F.3d at 1169.
125 Id. at 1172.
126 Id. (citing Tenn. Valley Auth. v. Hill, 437 U.S. 153, 194 (1978)).
127 Id.
128 Id. (citing United States v. Oakland Cannabis Buyers’ Co-op., 532 U.S. 483, 497
(2001)).
129 Id. at 1172, n.2.
130 McIntosh, 833 F.3d at 1169–75.
131 U.S. CONST. Art I. § 9, cl. 7.
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claims pertaining to separation of powers.132 In his motion to dismiss the
federal government’s complaint, individual appellant McIntosh argued
given that the government’s own complaint noted that the defendants were
operating under California’s state medical marijuana laws with state
issued permits and tax registration, the federal government clearly
prevented California from implementing its own laws.133 The court
addressed the Supremacy Clause in a footnote, merely noting that § 542
did “not provide immunity from Federal prosecution”, and that no state
law actually legalizes the “possession, distribution, or manufacturing of
marijuana.”134 While the CSA remains in effect, states cannot authorize
activity that remains prohibited by federal law.135
The court engaged in statutory interpretation to determine if there
truly was a constitutional violation of the appropriations bill by including
the Amendment.136 The court emphasized that under appropriations law,
it could only consider the text of the Amendment, not any “expressions of
intent” from any legislative history.137 Unless otherwise defined, the court
stated, “words will be interpreted as taking their ordinary, contemporary,
common meaning.”138 After assessing the common meaning of the words
“them”, “their own laws,” and “implement,” the court found that § 542, as
written, prohibits the DOJ from financing actions that impact medical
marijuana states from giving practical effect to their own laws authorizing
the use, distribution, possession, or cultivation of medical marijuana.139 In
its defense, the DOJ unsuccessfully argued that by taking action against
private individuals and not against the states themselves, it was not in
violation of the Amendment, and it was not preventing states from
enforcing their own laws.140 The court stated that the DOJ, by taking
actions against individuals as opposed to states, prevented the states from
giving effect to their own laws that specifically provide for “nonprosecution of individuals who engage in permitted conduct.”141
It is important to note that the court was explicit in stating two
principles: (1) that § 542 only applies to lawful medical marijuana use,
distribution, and cultivation; and (2) that it applies to a wide variety of

132
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135
136
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McIntosh, 833 F.3d at 1175.
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Id. at 1176.
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laws in flux,142 limiting power of the executive branch to some extent.143
To establish these principles, the court returned to interpreting the
Amendment, finding that the ordinary meaning of the Amendment
restricts the DOJ from allowing states to implement their laws that only
authorize medical marijuana use. 144
The court emphasized that no state law may legalize “possession,
distribution, or manufacturing of marijuana.”145 In remanding the case,146
the court did not provide much guidance for district courts who must
determine the precise remedy “in the first instance and in each case.”147
The decision tipped its hat to Gonzales in a footnote by stating: “[u]nder
the Supremacy Clause of the Constitution, state laws cannot permit what
federal law prohibits. Thus, while the CSA remains in effect, states cannot
authorize the ‘manufacture, distribution, or possession of marijuana’. Such
activity remains prohibited by federal law.”148
This decision is not necessarily a political one. The ruling on the
basis of the law itself does not cater to one side or another, especially given
the support for the Amendment,149 but rather looks strictly to the plainmeaning of words at issue in the Amendment as opposed to outside intent,
a factor which could otherwise persuade a judge if he or she agrees with
such intent.150 McIntosh makes clear that the issues from Gonzales are still
present even though, more than a decade later, states continue to legalize
marijuana through the democratic process.151
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Perhaps referring to state recreational laws in effect across the country.
McIntosh, 833 F.3d at 1178.
144 Id.
145 Id. at 1179, n.5.
146 See United States v. McIntosh, No. 14-cr-00016-MMC-1, 2017 U.S. Dist. LEXIS
39920 (N.D. Cal. Mar. 20, 2017) (noting that the Ninth Circuit’s holding does not constitute
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147 McIntosh, 833 F.3d at 1179.
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149 See supra note 108.
150 McIntosh, 833 F.3d at 1178.
151 See Steve Birr, Activists Hopeful Marijuana Ballots Will Spark Nationwide Reform,
THE DAILY CALLER (Oct. 28, 2016, 7:19 PM), http://dailycaller.com/2016/10/28/activistshopeful-marijuana-ballots-will-spark-nationwide-reform/ (citing California’s Proposition
64: that “would allow anyone over 21 to possess one ounce of Marijuana and grow up to
six plants in their home, with a 15 percent tax on any sales. Experts say that California
often serves as the national model for legislative reforms.”); California is spearheading the
movement and other states (Arizona, Maine, Massachusetts, and Nevada) have recreational
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there would still be contention between the federal government and the states.
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C. Congress and the Executive Branch post-McIntosh
Section 542 is a clever workaround to the CSA. In addressing this
apparent contradiction, the Ninth Circuit concluded that the DOJ can still
prevent states from implementing medical marijuana laws that violate
federal law, despite any medicinal purposes or state-wide acceptance.152
What the DOJ cannot do, however, is spend a penny to prosecute
individuals in states with valid medical marijuana laws if those laws are
being followed.153 The DOJ, however, is not rendered completely
powerless in light of this ruling; it is merely prevented from spending
funds to prosecute.154 The agency is not in violation of the FarrRohrabacher Amendment if it pursues individuals, for example, who
engage in marijuana-related conduct in states without protective laws.155
Additionally, the agency is free to spend the funding allotted to make it
more difficult for states’ medical marijuana programs to function even
under state law by increasing oversight, investigation, and surveillance of
growers, dispensaries, possibly patients, and the resources necessary for
businesses to survive.156 Equally as important, the Amendment does not
limit the DOJ from using funds to prosecute in states that do not have
medical marijuana laws.157
The Ninth Circuit was very aware of Congress’s ability to control
federal purse-strings, foreshadowing that “this temporary lack of funds”
could continue if Congress decides to include the Amendment in future
bills.158 President Obama did extend the Amendment when he signed into
law the 2017 Continuing Appropriations and Military Construction,
Veterans Affairs, and Related Agencies Appropriation Act.159 The Act
does not contain the exact language of the Amendment but does state that
funds previously made available under provisions in the 2016 measure are
to be extended.160 There is no specific wording allowing previously
untouchable United States Treasury funds to be made available to the DOJ
152
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Conflicting Approach Toward Medical Marijuana, LAW360.COM (Jan. 13, 2016, 11:30
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156 See Hurteau, et al. supra note 104; see also 2013 Cole Memo, supra note 67
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to prosecute medical marijuana claims under the CSA.161 The DOJ is
forced to pick and choose its battles, as it cannot spend federal funds to
prosecute individuals who lawfully engage in permissible conduct under
state law.162 If the federal government does choose to prosecute, according
to the McIntosh court, “it has prevented the state from giving practical
effect to its law providing for non-prosecution of individuals who engage
in the permitted conduct.”163
It is also clear that there is no protection afforded by the Amendment
alone in the face of federal enforcement, even if the states allow for
medical marijuana use:
The . . . observation should also serve as a warning. To be
clear, § 542 does not provide immunity from prosecution for federal
marijuana offenses. The CSA prohibits the manufacture, distribution, and
possession of marijuana. Anyone in any state who possesses, distributes,
or manufactures marijuana for medical or recreational purposes (or
attempts or conspires to do so) is committing a federal crime. The federal
government can prosecute such offenses for up to five years after they
occur.164
Congress “chose to proscribe preventing states from implementing
laws that authorize the use, distribution, possession, and cultivation of
medical marijuana,” but this is not a fixed or a permanent stance.165 As it
stands, neither meaningfully changes marijuana’s status under federal law
nor does it restrain the executive branch from enforcement.166 Even
though the appropriations bill was extended, the Amendment could be
taken out in the next iteration, or Congress may change its mind entirely
and appropriate funds for prosecutions if and when it so chooses.167
Moreover, because of how controversial the Amendment is, a court
in a different jurisdiction could interpret the statute differently and hold
the opposite of the Ninth Circuit.168 Any decision regarding marijuana is
161
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not Congress’s alone, either.169 The Ninth Circuit is cognizant that a new
administration could also shift the nation’s priorities, casting more
ambiguity on the future of medical marijuana.170 With the Cole and Ogden
memos providing states with some assurance that the federal government,
at least under the Obama Administration, would not enforce the marijuana
prohibition in every instance, it is no surprise that the Farr-Rohrabacher
Amendment reflects the Obama Administration’s view on medical
marijuana consistent with its DOJ memos.171
V. MEDICAL MARIJUANA IN THE FUTURE
Medical marijuana has had a long, strange trip172 in Washington but
where shall it go next? Writing in 2011, Professor Martin D. Carcieri of
San Francisco State University stated that he expected federal marijuana
prohibitions to reach a tipping point in 2013 and that, because Congress
was failing to take the lead on the matter, it would have to yield—most
likely—to the states.173 Four years and one administration change later,
the new Commander-In-Chief has options, assuming that Congress
extends the Farr-Rohrabacher Amendment beyond 2017. Subsection A
will discuss the options before the new administration and the likelihood
of success for each. Subsection B will advocate for keeping the status quo
from the Obama Administration to allow for additional scientific research
in order to form a more educated decision on the future status of medical
marijuana.
A. The Trump Administration’s Options
President Trump appointed several anti-marijuana figures to his
administration and while he was swift to act on issues such as abortion174
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http://reason.com/blog/2011/06/30/white-house-overrides-2009-mem.
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173 Martin D. Carcieri, Obama, the Fourteenth Amendment, and the Drug War, 44
AKRON L. REV. 303, 331 (2011).
174 See generally Lanae Erickson Hatalsky and Nathan Kasai, Donal Trump’s Coming
Abortion Surge, U.S. News and World Report (Oct. 18, 2017, 12:00 PM)
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and immigration,175 as of the writing of this Comment, there is no official
support for or rejection of medical marijuana. Two individuals in
particular play a decidedly large role in the future of marijuana, regardless
of whether they remain with the administration or not. Attorney General
Jeff Sessions stated on record that marijuana is a gateway drug.176 He also
said that marijuana legalization should be resisted, yet he has not provided
any specific plans to challenge state-regulated markets.177 Attorney
General Sessions previously criticized President Obama during a Senate
hearing for his admission of smoking marijuana in high school.178 Tom
Price, the Former Secretary of HHS, was also a marijuana opponent.179
John Hudak of the Brookings Institution has stated that Price has
consistently voted against marijuana policy reforms, even those modest
ones, and the medical community, of which Price is a part, is conservative
about the use of marijuana.180 Interestingly, although Secretary Price, then
a congressman, voted against various measures that would have prevented
the DOJ from interfering with state medical marijuana laws, during his
tenure Price did support “a limited measure preventing the DOJ from
interfering with states that allow the medical use of cannabidiol.”181
Despite his resignation, President Trump could seek to fill the position
with someone with similar views to Former Secretary Price to suggest
status quo on the issue.
Throughout his campaign and through mid-2017, President Trump
distinguished medical marijuana from recreational marijuana, expressed
support for medical marijuana, and stated that legalization should be

175 See generally Maryam Saleh, One Year of Immigration Under Trump, THE
INTERCEPT (Dec. 31, 2017, 12:00 PM) https://theintercept.com/2017/12/31/one-year-ofimmigration-under-trump/.
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Cabinet,
THE
https://www.washingtonpost.com/news/wonk/wp/2016/11/29/donald-trump-addsanother-marijuana-opponent-to-his-cabinet/?utm_term=.921d86164964.
180 Id.
181 Id.
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implemented on a state-by-state basis.182 In May 2017, his signing
statement pertaining to the passing of the Consolidated Appropriations Act
of 2017, 183 which upheld the Farr-Rohrabacher Amendment through
September 2017, conflicted with his previously expressed views.184 In the
short paragraph addressing medical marijuana, President Trump stated
that, he “will treat this provision consistently with [his] constitutional
responsibility to take care that the laws be faithfully executed.”185
The implication that President Trump could disregard the bill’s
limits on the use of DOJ money is nonsensical.186 Steve Bell, a Senior
Advisor at the Bipartisan Policy Center, stated that “[i]t is the
constitutional prerogative of the Congress to spend money and to put
limitations on spending,” and that President Trump’s signing statement is
“an extremely broad assertion of executive branch power over the
purse.”187
Attorney General Sessions has been an outspoken opponent of
marijuana, including its use for medicinal purposes. He made headlines
in the summer of 2017 for personally asking Congress to let him prosecute

182

See Berke, supra note 176. See also Jacob Sullum, Trump’s Medical Marijuana
Threat Contradicts the Law and His Own Position, REASON: HIT & RUN (May 8, 2017,
8:00 AM), http://reason.com/blog/2017/05/08/trumps-medical-marijuana-threat-contradi;
Tom Angell, Where Do Presidential Candidates Stand on Marijuana?, MARIJUANA.COM
(Apr. 13, 2015, 9:51 AM), https://www.marijuana.com/news/2015/04/where-dopresidential-candidates-stand-on-marijuana/; C.J. Ciaramella, White House Expects
‘Greater Enforcement’ Against States that Legalized Recreational Marijuana, REASON:
HIT & RUN (Feb. 23, 2017, 4:35 PM), http://reason.com/blog/2017/02/23/white-houseexpects-greater-enforcement.
183 Statement by President Donald J. Trump on Signing H.R. 244 into Law, THE WHITE
HOUSE
(May
5,
2017),
https://www.whitehouse.gov/the-pressoffice/2017/05/05/statement-president-donald-j-trump-signing-hr-244-law. It should be
noted that this statement is no longer available on the White House website as of the
completion of this comment.
184 While the actual signing statement is no longer available on the White House
Website, see supra note 185, there is considerable coverage on the statement itself. See
John Bowden, Trump Pushes Back Against Ban on State Medical Marijuana Interference,
THE HILL (May 5, 2017, 10:18 PM) http://thehill.com/policy/finance/332182-trumppushes-back-against-ban-on-state-medical-marijuana-interference; Carol Rosenberg an
Franco Ordoñez, Trump Warns He Might Not Obey Provisions on Guantánamo and Pot in
New Spending Law, THE MIAMI HERALD (May 5, 2017, 7:04 PM)
http://www.miamiherald.com/news/politics-government/article148944674.html; Jeremy
Berke, Trump Indicated Where He Stands on Medical Marijuana for the First Time Since
He
Took
Office,
BUSINESS INSIDER
(May
6,
2017,
12:15
AM)
http://www.businessinsider.com/medical-marijuana-trump-administration-2017-firststatement-2017-5.
185 See Berke, supra note 186.
186 See Sullum, supra note 184.
187 Id.
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medical-marijuana providers.188 In his May 1, 2017 letter, Attorney
General Sessions expressed his concern about the McIntosh decision, by
citing to a historic drug epidemic, the uptick in violent crimes, and an
alleged link between marijuana and the increased risk of psychiatric
disorders.189 The justification of a drug “epidemic,” however, does not
comport with actual data.190 For example, in January 2017, the National
Academies of Science, Medicine and Engineering found strong evidence
suggesting that marijuana is effective in dealing with chronic pain in
adults, as compared to a placebo.191 Attorney General Sessions may be
overstating the alleged danger of marijuana. While it may be habitforming, marijuana is significantly less addictive than opiates and has no
known lethal dosage192 (although earlier studies relied upon dosages given
to animals),193 unlike opiates. For chronic pain, many medical
professionals prescribe opiates, which have a high risk of abuse and
overdose.194 In 2013 alone, it was estimated that 1.9 million people either
“abused or were dependent on prescription opiates.195 In 2014, a study
188 Christopher Ingraham, Jeff Sessions Personally Asked Congress to Let Him
Prosecute Medical-Marijuana Providers, THE WASHINGTON POST (Jun. 13, 2017),
https://www.washingtonpost.com/news/wonk/wp/2017/06/13/jeff-sessions-personallyasked-congress-to-let-him-prosecute-medical-marijuana-providers/?utm_term=.f91d3
4c3a76d.
189 Letter from Jefferson B. Sessions III, Attorney General of the United States, to
Senators Mitch McConnell & Chuck Schumer, Speaker Paul Ryan, and Representative
Nancy
Policy
(May
1,
2017),
available
at
https://www.scribd.com/document/351079834/Sessions-Asks-Congress-To-UndoMedical-Marijuana-Protections.
190 See Ingraham, supra note 190.
191 Nearly 100 Conclusions on the Health Effects of Marijuana and Cannabis-Derived
Products Presented in New Report; One of the Most Comprehensive Studies of Recent
Research on Health Effects of Recreational and Therapeutic Use of Cannabis and
Cannabis-Derived Products, The National Academies of Sciences Engineering Medicine
(Jan.
12,
2017),
http://www8.nationalacademies.org/onpinews/newsitem.aspx?RecordID=24625&_ga=1.
198930671.1791292794.1484233196; Christopher Ingraham, Attorney General Sessions
Wants to Know the Science on Marijuana and Opioids. Here it is., THE WASHINGTON POST
(Feb. 28, 2017), https://www.washingtonpost.com/news/wonk/wp/2017/02/28/attorneygeneral-sessions-wants-to-know-the-science-on-marijuana-and-opioids-here-itis/?utm_term=.518798087372.
192 See Ingraham, supra note 193.
193 Id.; No, Marijuana is Not Actually “As Addictive as Heroin”, THE WASHINGTON
POST (Oct. 9, 2014), https://www.washingtonpost.com/news/wonk/wp/2014/10/09/nomarijuana-is-not-actually-as-addictive-as-heroin/?utm_term=.f60869a146f0; Marijuana
as
Medicine,
NATIONAL INSTITUTE OF DRUG ABUSE
(Apr.
2017),
https://www.drugabuse.gov/publications/drugfacts/marijuana-medicine.
194 Liz Szabo, Doctors Told to Avoid Prescribing Opiates for Chronic Pain, USA
TODAY (Mar. 15, 2016, 1:02 PM), https://www.usatoday.com/story/news/2016/03/15/cdcissues-new-guidelines-opiate-prescribing-reduce-abuse-overdoses/81809704/.
195 Id.

150

SETON HALL CIRCUIT REVIEW

[Vol. 14:125

showed that states that allowed for medical marijuana use between 1999
and 2010 had, on average, nearly 25% fewer opiate overdose deaths
compared to those states without.196 This study, however, has its limits in
that it is purely observational and only looks at the “correlation between
medical marijuana uptake and opiate deaths”; it is not “able to say that the
former definitively caused the decline in the latter.”197 One year later, the
National Bureau of Economic Research found that states with medical
marijuana dispensaries had a 15-35% decrease in “admissions to substance
abuse centers” and also saw a similar decline in deaths caused by opiate
overdose.198 Additionally, last year, another study reported that
individuals who used medical marijuana were “64 percent less likely to
report opiate use” and negative medical side effects and more likely to
report a good quality of life.199
Attorney General Sessions is not just up against public support for
medical marijuana,200 but he is also up against Congress. In July 2017, the
“Senate Appropriations Committee approved the Farr-Rohrabacher
Amendment by a voice vote”, meaning that the panel, including sixteen
Republicans, did not find the measure controversial.201 This is not
necessarily an issue of partisanship, as the Republican-controlled congress

196

Marcus A. Bachhuber, MD, et al., Medical Cannabis Laws and Opioid Analgesic
Overdose Mortality in the United States, 1999-2010, THE JAMA NETWORK: JAMA
INTERNAL
MEDICINE
(Aug.
25,
2014),
http://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1898878.
197 See Ingraham, supra note 193.
198 Id.; compare with Gregg Bishop, Opinions Differ About Whether Medical
Marijuana Can Help Curb Opioid Overdoses, ILLINOIS NEWS NETWORK (Aug. 11, 2017),
https://www.ilnews.org/news/health/opinions-differ-about-whether-medical-marijuanacan-help-curb-opioid/article_b31793b4-7df4-11e7-a336-f71d7b06986f.html.
199 See Ingraham, supra note 193; see also David Powel, Rosalie Liccado Pacula &
Mireille Jacobson, Do Medical Marijuana Laws Reduce Addictions and Deaths Related to
Pain Killers? (Nat’l Bureau of Econ. Research, Working Paper No. 12345, 2015),
http://www.nber.org/papers/w21345; see also Ashley C. Bradford and W. David Bradford,
Medical Marijuana Laws Reduce Prescription Medication Use in Medicare Part D, 35:7
HEALTH AFFAIRS 1230 (2016).
200 In April 2017, a Quinnipiac University Poll showed that 94% of participants
supported medical marijuana use. See U.S. Voter Support For Marijuana Hits New High;
Quinnipiac University National Poll Finds; 76 Percent Say Their Finances Are Excellent
Or
Good,
QUINNIPIAC
UNIVERSITY
POLL
(Apr.
20,
2017),
https://poll.qu.edu/national/release-detail?ReleaseID=2453.
201 Jacob Sullum, Rejecting Sessions’ Plea, Senate Panel Votes to Protect Medical
Marijuana,
REASON:
HIT
&RUN
(Jul.
27,
2017,
1:20
PM),
http://reason.com/blog/2017/07/27/rejecting-sessions-plea-senate-panel-vot; see also Full
Committee Markup of the CJS, THUS, and Legislative Branch Appropriations Bills for
FY2018, UNITED STATES SENATE COMMITTEE ON APPROPRIATIONS (JUL. 27, 2017, 10:30
AM), https://www.appropriations.senate.gov/hearings/full-committee-markup-of-the-cjsthud-and-legislative-branch-appropriations-bills-for-fy2018.
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has already included the measure in previous bills.202 Moreover, there
have been other congressional measures introduced that would expand the
Amendment including those that would allow “Department of Veterans
Affairs doctors to counsel patients on the use of medical marijuana”, those
that would even “legalize marijuana at the federal level”, and those that
would modify the “classification of marijuana to allow” precisely for what
this comment is advocating for: research.203
Despite this, in September 2017, the U.S. House Rules Committee
blocked the Farr-Rohrabacher Amendment, now known as the
Rohrabacher-Blumenauer amendment.204 However, President Trump and
Democratic leaders reached a budget agreement, which, among other
things, would extend the rider through December 2017.205 Unsurprisingly,
in order to avoid a government shutdown, Congress passed an emergency
resolution which extended the amendment, amongst other spending
provisions.206 This extension could help cannabis business owners come
into compliance with state laws without much threat of federal
enforcement.207 However, even if the Amendment is not renewed for the
next fiscal year, Attorney General Sessions could still try to shut down
state-licensed medical marijuana suppliers.208 In response to the House
Committee’s actions, Representatives Blumenauer and Rohrabacher
stated that:
By blocking our amendment, Committee leadership is putting at risk
the millions of patients who rely on medical marijuana for treatment, as
well as the clinics and businesses that support them. This decision goes
against the will of the American people, who overwhelmingly oppose

202 Nathan Howard, Congress is Heading for a Confrontation with Sessions over
Marijuana,
BLOOMBERG
(Aug.
3,
2017,
11:09
AM),
https://www.bloomberg.com/news/articles/2017-08-03/marijuana-fight-puts-congress-oncollision-course-with-sessions.
203 See Id.
204 The Farr-Rohrabacher amendment has since changed supporters given Senator’s
Farr retirement. See infra note 220. Trey Williams, Congress Gives Medical Marijuana
Users a Good Reason to be Paranoid, MARKETWATCH (Sept. 8, 2017, 6:54 AM),
http://www.marketwatch.com/story/house-blocks-medical-marijuana-budget-amendmentthat-would-protect-patients-2017-09-07; Debra Borchardt, Congress Puts Cannabis
Industry on High Alert, Blocking a Vote, FORBES (Sept. 7, 2017, 12:14 PM),
https://www.forbes.com/sites/debraborchardt/2017/09/07/congress-puts-cannabisindustry-on-high-alert-after-rejecting-vote/#128d8f5c51fc.
205 Supra Burns, note 90.
206 Jonathan Bach, Congress Saves Medical Marijuana Patients From Pot
JOURNAL
(Dec.
22,
2017),
Crackdown—For
Now,
STATESMAN
http://www.statesmanjournal.com/story/news/2017/12/22/congress-saves-medicalmarijuana-patients-pot-crackdown-now/977050001/.
207 Id.
208 See Burns, supra note 90, at 14.
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federal interference with state marijuana laws. These critical protections
are supported by a majority of our colleagues on both sides of the aisle.
There’s no question: If a vote were allowed, our amendment would pass
on the House floor, as it has several times before.209
President Trump has, so far, focused his policy agenda on other
issues despite his own expressed desire that states be allowed to decide if
marijuana is right for them. Given his work with Democratic leaders, there
could be hope. The administration has several options. First, the Trump
Administration could actually increase enforcement of marijuana
prohibitions in a variety of ways.210 Under this approach, there is likely to
be strong pushback from the states regardless of whether the Amendment
is included or not in the budget. Any attempts at prosecuting individuals
in states with valid medical marijuana laws would likely violate the Ninth
Circuit’s holding in McIntosh, even though the court insulated itself by
specifically stating that policies can change and assumed no congressional
action would change the Amendment.211 Individuals in the marijuana
industry, however, are hopeful that the Trump Administration realizes any
crackdown against “broadly popular laws” in states will create political
issues, and it should instead focus on other areas.212 Even if existing
markets are left alone, new states may be blocked or delayed from
legalizing medical marijuana by excluding those states from the
Amendment in any future version or by being intentionally vague on the
issue to keep state legislatures in abeyance.213
If the Amendment is not included in any future budgets, this could be
problematic for suppliers and individuals who rely on medical marijuana,
but it does not take away from the legality of the Ninth’s Circuit’s ruling.
The issue was brought to the judicial forefront and it is still a pressing
issue.214 The disconnect amongst the branches will undoubtedly create a

209

Id.
See infra Part II.
211 As of February 2017, two bills on the matter have been proposed, H.R. 1227, 117th
Cong. (2017) (Ending Federal Marijuana Prohibition Act of 2017) and H.R. 975, 117th
Cong. (2017) (Respect State Marijuana Laws Act of 2017). The latter bill was proposed
by Representative Rohrabacher and was initially introduced in 2013 and then again in
2015, prior to the passage of the Omnibus bill. See supra note 99.
212 See Berke, supra note 176.
213 Debra Borchardt, 5 Ways Trump Could Affect the Marijuana Industry, FORBES (Jan.
29, 2017, 11:46 AM), http://www.forbes.com/sites/debraborchardt/2017/01/20/5-waystrump-could-affect-the-marijuana-industry/#237ce54d5416.
214 In January 2018, Attorney General Sessions rescinded, allegedly without notice to
Congress, the Obama-era policy of discouraging prosecutors from bringing marijuana
charges in states where the drug is legal. See Charlie Savage and Jack Healy, Trump
Administration Takes Step that Could Threaten Marijuana Legalization Movement, THE
NEW
YORK
TIMES
(Jan.
4,
2018),
210
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vacuum. Such a vacuum will cause constitutional tension and a possible
showdown with the Trump administration by impacting states’ abilities to
give effect to their own laws.215 Justice O’Connor’s dissent in Gonzales
makes specific mention of the fact that because the state citizens
themselves voted for such measures, the federal government should not
interfere with the state’s choice.216 There is concern over whether there
will be enough votes to carry the Amendment into the future. Under 2017
House leadership, there has been a restriction regarding the scope of policy
riders to be considered in conjunction with the rule under which spending
bills are considered.217 In the event that the federal government chooses
not to incorporate the Amendment again, the protection ceases to exist,
which could set the medical marijuana industry back, even with state
authorization and public approval.218 There are organizations219 and
individuals on both sides of the political aisle that are fighting to ensure
state medical marijuana laws are honored under the Trump
administration.220 Disturbing the will of the people could drag the country
to court, forcing a divided Supreme Court to make the ultimate decision.
The Trump Administration’s second option is to keep the status quo
established by the Obama Administration’s DOJ memos and the passage
of the Farr-Rohrabacher Amendment.221 This approach would also mean
https://www.nytimes.com/2018/01/04/us/politics/marijuana-legalization-justicedepartment-prosecutions.html.
215 Lydia Wheeler, Trump’s DOJ Gears Up for Crackdown on Marijuana, THE HILL
(Jul. 23, 2017, 7:30 AM), http://thehill.com/regulation/administration/343218-trumps-dojgears-up-for-crackdown-on-marijuana.
216 Gonzales v. Raich, 545 U.S. 1, 43 (2005). (O’Connor, J, dissenting).
217 Id.
218 See Borchardt, supra note 213, at 1.
219 About Us, UNITED STATES CANNABIS COALITION, https://uscannabiscoalition.org/.
220 Tom Angell, GOP Congressman Wants Trump to Help Legalize Medical
(Oct.
24,
2017,
1:59
PM),
Marijuana,
FORBES
https://www.forbes.com/sites/tomangell/2017/10/24/gop-congressman-wants-trump-tohelp-legalize-medical-marijuana/#445330b33ddb.
221 The new medical cannabis rider is now referred to as the Rohrabacher-Blumenauer
amendment. Earl Blumenauer (D.-OR) has replaced outgoing Representative Sam Farr as
a co-sponsor of the rider. Jeremy Berke, The House Rules Committee Just Blocked a Vote
on a Critical Cannabis Amendment, BUSINESS INSIDER (Sep. 7, 2017, 3:22 PM),
http://www.businessinsider.com/house-rules-committee-blocks-vote-on-rohrabacherblumenauer-amendment-2017-9. See also Vince Sliwoski, BREAKING NEWS: Congress
Will Continue Protecting State Medical Marijuana Programs, CANNA LAW BLOG (May 1,
2017), http://www.cannalawblog.com/breaking-congress-will-continue-to-protect-statemedical-marijuana-programs/ (noting the current language of the bill as follows:
SEC. 537. None of the funds made available in this Act to the Department of Justice may
be used, with respect to any of the States of Alabama, Alaska, Arkansas, Arizona,
California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois, Iowa,
Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi,
Missouri, Montana, Nevada, New Hampshire, New Jersey, New Mexico, New York, North
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the executive branch would operate under the Obama-era internal
guidance and would provide for minimal federal intrusion. Even though
the DEA already refused to reclassify marijuana once, President Trump
changed his stance on various issues since his inauguration, a fact that
could prove useful to medical marijuana advocates.
A task force, comprised of prosecutors and federal law enforcement
officials, assembled by Attorney General Sessions himself may have
already started down this track. As of August 2017, the Task Force on
Crime Reduction and Public Safety has not offered new policy
recommendations to advance Attorney General Sessions’ anti-marijuana
views and in fact, it encourages continued research to determine whether
the Obama-era hands-off policy should be changed or rescinded.222 Pride
may also be at play, as John Hudak of the Brookings Institute notes: “If
they come out with a more progressive, liberal policy, the attorney general
[sic] is just going to reject it. They need to convince the attorney general
that the recommendations are the best they can do without embarrassing
the entire department by implementing a policy that fails.”223 Despite
Attorney General Sessions’ plea to Congress, the report “says officials
should continue to oppose rules” blocking the DOJ from interfering states
that allow for medical marijuana use and distribution where it is
allowed.224 Even with letters sent to the governors of Colorado and
Washington asking how the states would address reports of their
inadequacy in regulating marijuana,225 some members of Congress are not
worried about a change. They pointed to comments the Attorney General
made during his Senate confirmation, whereby he stated his opposition to
legalizing marijuana, but added the caveat that he understands the limited
federal resources, echoing those Democrats before him.226
The
recommendations were provided on a rolling basis but nevertheless,
Attorney General Sessions has been preparing to target legal cannabis in
Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina,
Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and
Wyoming, or with respect to the District of Columbia, Guam, or Puerto Rico, to prevent
any of them from implementing their own laws that authorize the use, distribution,
possession, or cultivation of medical marijuana)
222 Sadie Gurman, Huff, Puff, Pass? AG’s Pot Fury Not echoed by Task Force,
ASSOCIATED
PRESS
(Aug.
5,
2017),
https://apnews.com/ad37624fcb8e485a8d57a013d48a227c.
223 Id.
224 Id.
225 Id.; See also Matt Ferner, Legal-Weed States Tell Jeff Sessions Their Programs Are
Working. He Might Crack Down Anyway, THE HUFFINGTON POST (Aug. 3, 2017, 9:12 PM),
http://www.huffingtonpost.com/entry/legal-weed-jeffsessions_us_59834257e4b06d488874a716.
226 See Gurman, supra note 222.
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at least three of the eight states that have legalized recreational
marijuana.227
The status quo alleviates pressure on the Supreme Court to resolve
this controversial issue. A potential circuit split could occur depending on
what the state laws are at the time of a decision. For example, a medical
marijuana decision appealed to a post-McIntosh Ninth Circuit may not be
the same as a medical marijuana case appealed to the Sixth Circuit.228 The
Supreme Court would probably not take up another medical marijuana
case absent a circuit split, especially in light of strong public support,
despite a Republican-controlled federal government.229 If the Court does
take a case, it should do so on a non-partisan basis, a concept not so
farfetched given the Ninth Circuit’s ruling in McIntosh. Should the Court
ultimately decide to hear a case and rule against the Amendment, this may
not stop states from continuing to legalize medical marijuana, as has been
the case post-Gonzales, which would only drag out the state-federal
government tension. Thus, the burden is on Congress to either amend the
CSA or exempt the substance all together, provided the states can show
successful and legal use of medical marijuana and can offer valid and
reliable results from such use.230
Third, the new administration could take steps to legalize medical
marijuana independent of legalizing recreational marijuana more
generally. The third option is, in a way, the end result of option two.
Option three cannot, and certainly will not happen, without strong and
convincing evidence that medical marijuana should be considered a
legitimate form of medical relief. The DOJ memoranda allowing states to
continue experimenting with legalized medical marijuana or Congress
choosing to remove marijuana, or at least medical marijuana, from

227

Mark Joseph Stern, Sessions’ Marijuana Crackdown May Still Be Coming, SLATE
(Aug.
7,
2017),
http://www.slate.com/articles/news_and_politics/jurisprudence/2017/08/jeff_sessions_wil
l_probably_crack_down_on_legal_marijuana_despite_his_experts.html.
228 United States v. Samp, 2017 U.S. Dist. LEXIS 46291 (E.D. Mich. Dec. 13, 2016)
(requiring an evidentiary hearing to see if defendant complied with Michigan’s medical
marijuana law, stating that “if the Government can prove, by a preponderance of the
evidence, that Samp was not in full compliance with the Michigan medical marijuana law,
then the Government will be allowed to continue prosecuting”).
229 See Nebraska, et al. v. Colorado, 136 S. Ct. 1034 (2016) (denying a motion for leave
to file a bill of complaint in a suit brought by Nebraska Attorney General John Bruning
and Oklahoma Attorney General Scott Pruitt against Colorado over its marijuana
legalization law); see also Adam Liptak, Supreme Court Declines to Hear Challenge to
Colorado’s Marijuana Laws, THE NEW YORK TIMES (Mar. 21, 2016),
https://www.nytimes.com/2016/03/22/us/politics/supreme-court-declines-to-hearchallenge-to-colorados-marijuana-laws.html?_r=0.
230 See Contorno, supra note 4.
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Schedule I could create thousands of jobs nationwide.231 Moreover, there
could be more economic benefits, such as fees and taxes generated from
allowing the states more freedom to experiment with operating under a
legalized medical marijuana system.232
B. A Scientific Argument for the Status Quo
This Comment posits that the best approach is a scientific one. It is
scientifically more productive to keep the status quo in terms of
enforcement, allowing for the opportunity for new research channels either
by expanding those eligible to conduct that research, or by allowing states
to spend their own funds to carry out such studies. The federal
government’s monopoly on research and its refusal to privatize FDAapproved research has severely hampered researchers’ attempts to
legitimize marijuana as a legal prescription medicine.233 If Congress does
not want to expand the number of individuals or corporations eligible for
researching the drug using any federal funding, it can let the states provide
funding. By doing so, the states would be able to provide closely
monitored, in-depth studies as to the efficacy of medical marijuana.
State institutions and agencies, such as medical boards, departments
of healthcare services, public universities, and research hospitals would be
the ideal battle labs for such studies. In fact, a recent study showed that
medical provides were the ability to prescribe medical marijuana to
patient, including children, “strong supported clinical trials to investigate
its use [particularly, for example,] in children.”234 By granting more access
to engage in clinical trials, Congress would be able to make an intelligent
decision based upon ample results, allowing it to either amend the CSA to
provide an exception for medical marijuana or to uphold its prohibition.
If the states were paying for research facilities and operations with their
own revenue, they would more easily provide expanded medical

231
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232 Susan K. Livio, Medical Pot Program Continues to Grow, THE STAR LEDGER (Feb.
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(Jun.
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2017,
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233 See Stern and DiFonzo, supra note 32.
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marijuana-based services to their own citizens without having to request
any assistance from the federal government.235
This approach also follows the strong federalism expressed by
Justice O’Connor’s dissent in Gonzales.236 This dissent is important
because it provides the best solution for obtaining the best results to make
the best choice about marijuana. It also would allow states to operate
without pressure from potential federal enforcement even if they are
following their own laws.237 Even though states have passed medical
marijuana legislation, they are kept in abeyance of federal prosecution and
are left wondering if, or rather when, the federal government will enforce
the CSA against citizens who lawfully abide by the state measures.
Allowing states to give effect to their own laws while the federal
government stays in abeyance would alleviate the possibility of fruitless
government intervention. If Congress is content with the results arising
out of the states after a reasonable and appropriate period of observation
and monitoring, it could expand the Farr-Rohrabacher Amendment to
include all states.
Alternatively, the DOJ could issue new guidance to ensure the states
and the federal government understand each other’s positions and can
operate relatively freely under the current administration.238 President
Trump has already proven to be flexible on his campaign rhetoric and his
ever-active Twitter account, and as of December 2016, produced no
mention of the word “marijuana”.239 Before the appointment of Attorney
General Sessions, marijuana opposition was removed from the White
House website, suggesting that maintaining the status quo will allow the
administration to focus on other priorities, and save the government the
money and effort required to fight an unnecessary drug war.240 The FarrRohrabacher (now Rohrabacher-Blumenauer) Amendment helps check
the government and should remain as is for the time being. Allocating
235

Id.; See also John Ingold, DEA Gives Approval to Colorado-Funded Study on
Marijuana and PTSD, THE DENVER POST (Apr. 22, 2016, 7:28 AM),
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funds to raid businesses that are operating validly under state law will
likely anger constituents of members of Congress from marijuana states
from marijuana states.241
Science is the best and most effective way to address the legalization
of marijuana. We live in a time of scientific uncertainty. Agencies, and
the scientific community more broadly, are under a tremendous amount of
scrutiny.242 Even more than the attack on science is the attack on the health
of seriously ill Americans who, because of federal oversight, may be
denied alternative treatment options, exacerbating already debilitating
illnesses. In cases like Charlotte Figi’s,243 parents are forced to keep their
children on strong pharmaceuticals that may cause severe side effects and
offer only marginal relief.244 In 2017, Melvin Washington, a retired NFL
player; Alexis Bortell, an eleven-year-old girl with severe epilepsy; and
Jose Belen, a disabled veteran with PTSD, filed suit against Attorney
General Sessions, the DEA, and the DOJ over the constitutionality of the
CSA and the listing of marijuana as a Schedule I drug.245 The suit alleges
that by classifying cannabis as a Schedule I drug, methamphetamines and
cocaine (Schedule II drugs) are considered more benign than marijuana
thus rendering the classification “irrational” and in violation of the
Constitution.246 In light of this irrationality, “the federal government is
aware that the system is flawed,” according to the plaintiffs.247
This Comment suggests that there could be potential medicinal
benefits from marijuana more broadly, and not just from low-THC medical
cannabis.248 Limiting research in this way poses serious consequences for
those with no other option. Moral opposition to marijuana does not
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preclude positive scientific results. For the federal government to say
there is no medical benefit249 while restricting research, as opposed to
allowing private entities or state-funded agencies,250 universities, or
hospitals to research is to effectively not “pass the pipe” of research.251
Private pharmaceutical firms and state-institutions would be ideal
experiment laboratories because of non-federal funding. In keeping its
monopoly over research outlets, the federal government is harming those
who could benefit from marijuana medically. 252 In coveting research,
there can be no progress in the scientific or medical communities.
VI. CONCLUSION
This Comment advocates for the government to formally allow for
more private and state-funded research opportunities. If Congress feels
compelled to regulate this, it would be beneficial to at first allow states
with medical marijuana laws to do such research. Congress could provide
249
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the oversight and guidelines to those private and state actors studying
marijuana but, before it can do that, it must be clear in its decision to
suspend enforcing the CSA in order to alleviate the threat of possible
enforcement, which was discretionary under the Obama Administration.
If enforcement continues to be discretionary under the Trump
Administration, there must be guidance as to which states may participate
in and fund this scientific research. Only then will Congress be able to
once and for all remove medical marijuana from the Controlled Substance
Act.
There is no way to make an intelligent decision about medical
marijuana without allowing for all research avenues to be explored.
Advancing society can only be done by advancing scientific objectives
anything short of that cripples the future, whether it is with regard to
medical marijuana as a federally permissible treatment option or more
generally. Science is vital to societal progression. Medical marijuana is
progress for those who are out of treatment options for serious illnesses or
may even open the door to other medicinal capabilities. Medical
marijuana has a place in society as well, as demonstrated by continuously
growing state and public support.253 When medical marijuana is
distributed in accordance with state law, it is properly prescribed, and that
is progress. The current consensus in the country leans towards support for
medical marijuana;254 there is just a difference in the details as to how it
should be legalized and regulated. In order to get to a point where
marijuana is properly distributed and regulated, the federal government
must turn to science. Science can help raise awareness about marijuana’s
effectiveness, or it could show that it is not helpful. Without research,
however, there is no way to know for sure.
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